|
Factors
| |
Responder
|
Non-responder
|
P-value
|
|---|
| | |
CR + PR (n = 15)
|
SD + PD (n = 20)
| |
|---|
|
Age (yrs)
|
≤60
|
7
|
14
|
0.163
|
| |
>60
|
8
|
6
| |
|
Gender
|
Male
|
12
|
16
|
1.000
|
| |
Female
|
3
|
4
| |
|
ECOG
|
1
|
8
|
10
|
0.845
|
| |
2
|
7
|
10
| |
|
Etiology
|
Viral
|
13
|
17
|
0.889
|
| |
Non-viral
|
2
|
3
| |
|
Child-Pugh classification
|
A
|
15
|
13
|
0.010
|
| |
B
|
0
|
7
| |
|
JIS score
|
2
|
14
|
12
|
0.026
|
| |
3
|
1
|
8
| |
|
Pretreatment AFP (ng/ml)
|
≤ 20
|
5
|
5
|
0.589
|
| |
> 20
|
10
|
15
| |
|
Type of HCC
|
Nodular
|
10
|
10
|
0.324
|
| |
Diffuse infiltrative
|
5
|
10
| |
|
Multiplicity
|
Solitary
|
8
|
16
|
0.093
|
| |
Multiple
|
7
|
4
| |
|
Location of thrombi
|
PV branch
|
9
|
8
|
0.241
|
| |
Main portal trunk
|
6
|
12
| |
|
BED (Gy10, mean ± SD)
| |
70.0 ± 6.5
|
68.1 ± 11.0
|
0.530
|
- Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ECOG, Eastern Cooperative Oncology Group; JIS, Japan integrated staging; AFP, α-fetoprotein; HCC, Hepatocellular carcinoma; PV, Portal vein; BED, biologically effective dose; SD, standard deviation.
- P-values are obtained by chi-square test, Fisher’s exact test, or t-test.
